{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:54:30Z","timestamp":1776848070717,"version":"3.51.2"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,7,15]]},"DOI":"10.2169\/internalmedicine.4178-19","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T22:03:48Z","timestamp":1585778628000},"page":"1755-1761","source":"Crossref","is-referenced-by-count":13,"title":["Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"59","author":[{"given":"Zenshi","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Nakamagoe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Neurogenetics, Department of Brain Research, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/neup.12149","volume":"35","author":"H Miyajima","year":"2015","unstructured":"1. Miyajima H. Aceruloplasminemia. Neuropathology 35: 83-90, 2015.","journal-title":"Neuropathology","ISSN":"https:\/\/id.crossref.org\/issn\/0919-6544","issn-type":"print"},{"key":"2","unstructured":"2. Nittis T, Gitlin JD. The copper-iron connection: hereditary aceruloplasminemia. Semin Hematol 39: 282-289, 2002."},{"key":"3","unstructured":"3. Marchi G, Busti F, Lira Zidanes A, Castagna A, Girelli D. Aceruloplasminemia: a severe neurodegenerative disorder deserving an early diagnosis. Front Neurosci 13: 325, 2019."},{"key":"4","unstructured":"4. Hida A, Kowa H, Iwata A, Tanaka M, Kwak S, Tsuji S. Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis. J Neurol Sci 298: 136-139, 2010."},{"key":"5","unstructured":"5. Vroegindeweij LH, van der Beek EH, Boon AJ, et al. Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series. Diabet Med 32: 993-1000, 2015."},{"key":"6","unstructured":"6. Calder GL, Lee MH, Sachithanandan N, Bell S, Zeimer H, Maclssac RJ. Aceruloplasminemia: a disorder of diabetes and neurodegeneration. Intern Med J 47: 115-118, 2017."},{"key":"7","unstructured":"7. Lindner U, Schuppan D, Schleithoff L, et al. Aceruloplasminemia: a family with a novel mutation and long-term therapy with deferasirox. Horm Metab Res 47: 303-308, 2015."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Badat M, Kaya B, Telfer P. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminemia. Br J Haematol 171: 430-432, 2015.","DOI":"10.1111\/bjh.13401"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bove F, Fasano A. Iron chelation therapy to prevent the manifestations of aceruloplasminemia. Neurology 85: 1085-1086, 2015.","DOI":"10.1212\/WNL.0000000000001956"},{"key":"10","unstructured":"10. Doyle A, Rusli F, Bhathal P. Aceruloplasminemia: a rare but important cause of iron overload. BMJ Case Rep. Forthcoming."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rusticeanu M, Zimmer V, Schleithoff L, et al. Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms. Clin Genet  85: 300-301, 2014.","DOI":"10.1111\/cge.12145"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tai M, Matsuhashi N, Ichii O, et al. Case of presymptomatic aceruloplasminemia treated with deferasirox. Hepatol Res 44: 1253-1258, 2014.","DOI":"10.1111\/hepr.12292"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Suzuki Y, Yoshida K, Aburakawa Y, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern Med 52: 1527-1530, 2013.","DOI":"10.2169\/internalmedicine.52.0102"},{"key":"14","unstructured":"14. Pan PL, Tang HH, Chen Q, Song W, Shang HF. Desferrioxamine treatment of aceruloplasminemia: long-term follow-up. Mov Disord 26: 2142-2144, 2011."},{"key":"15","unstructured":"15. Roberti Mdo R, Borges Filho HM, Gon\u00e7alves CH, Lima FL. Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. Rev Bras Hematol Hemoter 33: 389-392, 2011."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Finkenstedt A, Wolf E, H\u00f6fner E, et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 53: 1101-1107, 2010.","DOI":"10.1016\/j.jhep.2010.04.039"},{"key":"17","unstructured":"17. Skidmore FM, Drago V, Foster P, Scmalfuss IM, Heilman KM, Streiff RR. Aceruloplasminemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry  79: 467-470, 2008."},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Mariani R, Arosio C, Pelucchi S, et al. Iron chelation therapy in aceruloplasminemia: study of a patient with a novel missense mutation. Gut 53: 756-758, 2004.","DOI":"10.1136\/gut.2003.030429"},{"key":"19","unstructured":"19. Lor\u00e9al O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36: 851-856, 2002."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41: 404-407, 1997.","DOI":"10.1002\/ana.410410318"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kaneko K, Hineno A, Yoshida K, Ohara S, Morita H, Ikeda S. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum Pathol 43: 451-456, 2012.","DOI":"10.1016\/j.humpath.2011.05.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/14\/59_4178-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T03:31:02Z","timestamp":1595043062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/14\/59_4178-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":21,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4178-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}